Management of Patients With Upper & Obstructive Respiratory Disorders Flashcards

1
Q

Head & Neck Cancers

A

Squamous cell
Membrane lining respiratory tract
47,000 new cases per year
2% - 3% of all malignancies
Men: 2 – 5 x greater incidence

Risk factors
50 years or older
Prolonged use of tobacco & alcohol
Diet poor in fresh fruits & veggies
HPV infection: About 70% of oropharyngeal cancers are caused by HPV. In the United States, more than half of cancers diagnosed in the oropharynx are linked to HPV type 16

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Laryngeal Cancer

A

Glottic (True vocal cords)
Radiation provides 85% - 95% cure
Supraglottic (Above vocal cords)
Radiation
Partial Larygectomy
Subglottic (Below vocal cords)
Metastasis common
Total Laryngectomy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Radiation Site Skin Care

A

Use prescribed lotions / creams
Do not use within 2-hours of treatment
Apply with “patting”, not rubbing motion

Avoid:
Temperature extremes
Rough / tight clothing
Rubbing / scratching treated area

Notify MD of moist skin reaction immediately

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Dry mouth (Xerostomia)

A

Pilocarpine hydrochloride (Salagen) to increase saliva production
Increase oral fluids
Always carry a water bottle!
Sugarless gum or candy
Baking soda or glycerin mouth washes
Artificial saliva

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Stomatitis

A

Soft, bland foods
Relieve pain
Frequent mouth rinses with water
Suck on ice chips
Rinse & spit: Antacid, Diphenhydramine (Benadryl) & topical Lidocaine
Avoid
Commercial mouthwash
Hot / spicy foods

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Radical (En bloc) Neck Dissection

A

All the tissue on the side of the neck from the jawbone to the collarbone is removed. The muscle, nerve, salivary gland, and major blood vessel in this area are all removed.

Removal of:
Lymph channels / nodes (Selective)
Sternocleidomastoid muscle
Spinal accessory nerve (Sternocleidomastoid & trapezius neck muscles)
Modified “spares”
Jugular vein
Sub-mandibular tissue

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Surgical Complications

A

Airway obstruction
Hemorrhage
Expect blood-tinged tracheal secretions for 24-48 hours
Observe for: ??
Carotid artery rupture
Fistula

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Post-Operative Care

A

Risk for / Potential:
Aspiration
Ineffective airway clearance
Impaired gas exchange
Impaired nutrition (Less than requirements)
Infection

Surgical site
Wound drain; Expect small to moderate sero-sanguinous drainage for 48 – 72 hours
Tube feeding
Communication

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Parts of Tracheostomy Tube

A

A variety of tubes are available to meet individual patient needs.

All tracheostomy tubes contain a faceplate or flange, which rests on the neck between the clavicles and outer cannula.

In addition, all tubes have an obturator, which is used when inserting the tube. During insertion of the tube, the obturator is placed inside the outer cannula with its rounded tip protruding from the end of the tube to ease insertion. After insertion, the obturator must be immediately removed so air can flow through the tube. Keep obturator at bedside in case of accidental decannulation.

Tracheostomy tubes have an outer cannula (which keeps the airway patent) and an inner cannula (which can be disposable or nondisposable and removed for cleaning).

Cuffed and uncuffed tracheostomy tubes are available. A tracheostomy tube with an inflated cuff (balloon) is most commonly used, particularly if the patient needs mechanical ventilation or is at risk of aspiration. Cuffless tubes are primarily used for the patient with a long-term tracheostomy, making eating and talking possible.

The outer and/or inner cannula may be fenestrated or nonfenestrated. A fenestrated tube has an opening (a hole) on the surface of the tube. A fenestrated tube will allow the patient to breathe spontaneously.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

“Fenestrated” Trach tube for speaking:

A

Cuff deflated
Inner cannula removed
Trach tube capped
Allows air to pass over vocal cords

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Tracheostomy Safety Precautions

A

Obturator & tube of equal/smaller size kept at bedside
Tapes/ties not changed for at least 24-hours
First tracheostomy tube change usually performed by MD after 7-days
Once per month
Healed tract well formed after several months
Patient can be taught to change tube using clean technique

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Tracheostomy Care

A

Suction to remove secretions
Inner cannula care
Cleanse around stoma
Change ties

Cuffed tube used for risk of aspiration or mechanical ventilation
Minimal occlusive volume (MOV) to create an airway seal
Should not exceed 20 mm Hg or 25 cm H2O

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Accidental Dislodgment

A

Priority is to immediately replace tube
Grasp retention (“Stay”) sutures & spread opening
Insert obturator in replacement tube

Another method:
Insert suction catheter to allow for air passage & guide re-insertion
Thread tracheostomy tube over catheter
Remove suction catheter

Cannot replace tube?
Assess level of respiratory distress
Minor dyspnea may be alleviated with Semi-Fowler’s position
Severe distress may progress to respiratory arrest
Cover stoma with sterile dressing
Ventilate with bag-mask over nose & mouth until help arrives

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Decannulation

A

When patient can exchange air & manage secretions
Stoma closed with gauze & covered with occlusive dressing (tape)
Tissue forms in 24 to 48 hours
Opening will close in several days
Instruct patient to splint stoma with fingers when coughing, swallowing, or speaking

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Asthma

A

Pathophysiology
Reactive airway disease
Reversible in early stages
Characterized by broncho-spasm
Chronic inflammatory lung disease causes varying degrees of pathology - obstruction

Triggers
Drugs & Food Additives
Aspirin, NSAIDs, ACE inhibitors
Gastroesophageal Reflux Disease (GERD)
Psychological / Emotional Stress

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Asthma: Early-Phase

A

Inflammatory mediators cause early-phase response
Vascular congestion
Edema formation
Production of thick, tenacious mucus
Bronchial muscle spasm
Thickening of airway walls

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Asthma: Late-Phase

A

Late-phase response
Occurs within 4 to 6 hours after initial attack
Occurs in about 50% of patients
Can be more severe than early phase and can last for 24 hours or longer

Late-phase response
If airway inflammation is not treated or does not resolve, it may lead to irreversible lung damage
Structural changes in the bronchial wall known as remodeling

Corticosteroids are effective in treating this inflammation.

18
Q

Clinical Manifestations asthma

A

Most common manifestations
Cough
Shortness of breath (dyspnea)
Wheezing
Wheezing is an unreliable sign to gauge severity
Severe attacks can have no audible wheezing due to reduction in airflow
“Silent chest”: ominous sign of impending respiratory failure
Severely diminished breath sounds
Chest tightness
Variable airflow obstruction

Unpredictable and variable
Recurrent episodes of wheezing, breathlessness, cough, and tight chest
May be abrupt or gradual
Lasts minutes to hours

19
Q

Asthma: Health Promotion

A

Identify & avoid known triggers
Use dust covers
Use of scarves or masks for cold air
Avoid aspirin or NSAIDs
Desensitization can decrease sensitivity to allergens
Prompt diagnosis & treatment of upper respiratory infections and sinusitis may prevent exacerbation
Fluid intake of 2L to 3L daily
Adequate nutrition
Adequate sleep
Take -adrenergic agonist 10 to 20 minutes prior to exercising

20
Q

Acute Signs of Hypoxemia

A

Restlessness
Increased anxiety
Inappropriate behavior
Increased pulse & B/P
Pulsus paradoxus
Drop in systolic BP > 10 mm Hg during inspiration

21
Q

Asthma: Diagnostic Studies

A

Detailed history & physical
Pulmonary function tests
Peak expiratory flow rate (PEFR)
Chest x-ray
ABGs
Pulse oximetry
Allergy testing
Eosinophil levels
Sputum culture & sensitivity

22
Q

ABG’s

A

pH 7.35 - 7.45
Pco2 35 – 45 mm Hg
HCO 3 21 – 28 mEq/L
P02 80 – 100 mm Hg
O2 Sat 95% - 100%
O2 Content 15 – 22 vol%
Base Excess 0 +/ 2 mEq/L
Alveolar to Arterial 02 Difference < 10 mm Hg

23
Q

Asthma: Nursing Diagnoses

A

Ineffective airway clearance
Ineffective therapeutic regimen management
Anxiety
Goal: Decrease patient’s sense of panic
Stay with patient
Encourage slow, pursed lip breathing
Prolongs expiration
Position comfortably

24
Q

Treatment of Acute Asthma

A

Start O2 & monitor pulse oximetry or ABG’s
Short-acting -adrenergic agonists(SABA’s) by metered dose (Spacer or nebulizer)
Corticosteroids
May be added with insufficient initial response to SABA alone
Continue until patient:
Breathes comfortably
Wheezing has disappeared & signs of good air exchange are present
PFT’s are near baseline values

25
Q

Asthma: Acute Intervention

A

Monitor respiratory & cardiovascular systems
Lung sounds
Respiratory rate
Pulse
BP
ABGs
Pulse oximetry
FEV(forced expiratory volume) and PEFR (peak expiratory flow rate)
Work of breathing

Administer O2
Bronchodilators
Chest physiotherapy
Medications (as ordered)
Ongoing patient monitoring
Response to therapy

26
Q

Status Asthmaticus

A

Severe attack that does not respond to treatment
Life-threatening, risk for respiratory failure
Causes:

Clinical Manifestations
Increased airway resistance (Edema)
Mucous plugging
Bronchospasm - Air trapping & Hyperinflation
Potential complications:??

27
Q

Status Asthmaticus: Treatment

A

Supplemental O2
Mask or nasal cannula to achieve 90%
Increase frequency & dose of bronchodilators
Continuous -adrenergic agonist nebulizer therapy
Drug delivery at home may have been sub-maximal
Higher doses under supervision may be beneficial

IV Aminophylline may be added if no response to -adrenergic agonists
IV corticosteroids every 4-6 hours
Continuous monitoring
IV magnesium sulfate (Bronchodilator)
IV fluids for insensible fluid loss
Bronchoscopy (rare, to remove thick mucous plugs)

Move to higher level of care:
Arterial catheter; frequent ABG monitoring
Mechanical ventilation if no response to treatment
Sodium bicarbonate; treat metabolic acidosis

28
Q

Asthma: Other Complications

A

Rib fractures
Pneumothorax
Pneumo-mediastinum
Atelectasis
Pneumonia

29
Q

Patient Teaching: Inhalers

A

Difficulty using MDI?
Spacer or nebulizer
Clean by removing dust cap & rinsing with warm water
DPI (dry powder inhaler) requires less manual dexterity & coordination
Must be kept in dry place

Rinse mouth after steroid doses – reduces risk of oropharyngeal candidiasis, hoarseness and dry cough
May still be easier if after -adrenergic agonists

30
Q

COPD Description

A

Airflow limitation not fully reversible
Usually progressive
Abnormal inflammatory response of lungs, primarily caused by cigarette smoking and other noxious particles or gases
Emphysema and chronic bronchitis are similar lung conditions under the umbrella of COPD

31
Q

COPDSignificance

A

Third leading cause of death in United States
Kills more than 133,000 Americans each year

32
Q

COPDEtiology

A

Risk factors
Cigarette smoking
Occupational chemicals and dust
Air pollution
Severe recurring respiratory infections
α1-antitrypsin deficiency

α1-antitrypsin deficiency (an autosomal recessive disorder) is a risk factor for developing COPD.
Some degree of emphysema has been thought to occur as a person ages. It is caused by changes in the lung structure and the respiratory muscles, even in a nonsmoker.

33
Q

A1-Antitrypsin Deficiency

A

Genetic risk factor
Autosomal recessive
(Lung/liver)
Inhibits breakdown of lung
Proteolytic enzymes
Neutrophils & macrophages
Smoking greatly exacerbates disease process

Onset by 40 years
Minimal tobacco
Family Hx
Chronic liver disease (infant/adult)
Northern European

34
Q

COPDCigarette Smoking

A

Clinically significant airway obstruction develops in 15% of smokers
COPD should be considered in any person who is over 40 with a smoking history of 10 or more pack-years
Effects of nicotine
Stimulates sympathetic nervous system

35
Q

COPDOccupational & Environmental

A

COPD can develop with intense or prolonged exposure to
Dusts, vapors, irritants, or fumes
High levels of air pollution
Fumes from indoor heating or cooking with fossil fuels

36
Q

COPDPathophysiology

A

Common characteristics
Mucus hypersecretion
Dysfunction of cilia
Hyperinflation of lungs
Gas exchange abnormalities

37
Q

COPD Manifestations

A

Progressive
Dyspnea on exertion to
Dyspnea at rest
Enlarged A-P diameter of chest
Percussive hyper-resonance
CXR: Over-inflation & flat diaphragm

Compensated respiratory acidosis (Late)
Cardiac enlargement & Right ventricular lift
ECG: Right heart strain pattern and axis deviation
Cyanosis, neck vein distention & pitting edema

38
Q

Management of COPD

A

Prevent respiratory infection
Improve ventilation
Bronchodilators
-adrenergic agonists
Methylxanthines (Theophylline)
Anti-cholinergics (Ipratroprium)
Glucocorticoids
Long-term oxygen

Remove / control secretions
Reduce complications
DVT prophylaxis
Influenza vaccine
Pneumonia vaccine
Promote exercise
Improve general health / nutrition

39
Q

Other Therapies for COPD

A

Surgery
Lung volume reduction
Bullectomy
Lesions > 1 cm
Lung transplantation
Pursed-lip breathing

Airway clearance
Effective (Huff) coughing
Chest PT
Postural drainage
Airway clearance devices
Acapella
High-frequency chest wall oscillation

40
Q

COPD Complications

A

Right-sided heart failure (Cor Pulmonale)
Exacerbations
Acute respiratory failure
Depression
Anxiety

41
Q

Chronic Bronchitis

A

Destruction of cilia in airways of lungs. Airways then become inflamed and narrower, making breathing difficult
Inflammation
Increased mucous production
Chronic cough
Scarring
At least 3-months for two consecutive years

Abnormal V/Q ratio
Fall in PaO2
Impaired ventilation may increase PaCO2
Polycythemia
Compensation for hypoxemia

42
Q

Emphysema

A

Obstruction results from destruction of alveolar walls which leads to permanent over-distention of air spaces
Destruction of pulmonary capillaries further decreases oxygen V/Q (ventilation-perfusion)
Centriacinar (Smokers)
Panacinar (alpha-1 antitrypsin deficiency)
Paraseptal (Spontaneous pneumothorax)

Centriacinar begins in the respiratory bronchioles and spreads peripherally mainly in the upper half of thelungs.
Panacinar predominates in the lower half of the lungs and destroys the alveolar tissue.
Paraseptal emphysema preferentially localizes around the septae of the lungs or pleura, often associated with inflammatory processes, like prior lung infections.